AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6816006 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 25 or 50 mg/kg body weight twice a day for 5 days
Number of subjects: 297
Study 6816006 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 25 mg/kg body weight twice a day for 10 days
Number of subjects: 297
Study 31818723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (N = 35)
Number of subjects: 65
Study 31818723 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) (N = 30)
Number of subjects: 65
Study 30634007 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability of attentional bias (AB) for food stimuli
Number of subjects: 3
Study 30634007 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability of reaction time (RT) on filler trials
Number of subjects: 3
Study 30634007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean AB score
Number of subjects: 3
Study 30634007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dwell time variability
Number of subjects: 3
Study 30385543 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily work breaks in a hospital-integrated garden
Number of subjects: 29
Study 30385543 — intervention group
Group type: COMPARATOR
Intervention: Indoor-only breaks
Number of subjects: 29
Study 26815178 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise treadmill test to exhaustion
Number of subjects: 59
Study 25133177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine + 8.4% NaHCO3 (Group PN)
Number of subjects: 64
Study 25133177 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine (Group P)
Number of subjects: 64
Study 22297687 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple CDS
Number of subjects: 41
Study 22297687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted CDS
Number of subjects: 41
Study 22297687 — intervention group
Group type: COMPARATOR
Intervention: Control (no CDS)
Number of subjects: 41
Study 19614689 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI(2) (10 ng kg(‐1) min(‐1) infusion over 25 min)
Number of subjects: 12
Study 19614689 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI(2)
Number of subjects: 12
Study 17427824 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite bonding agent with light activation
Number of subjects: 120
Study 17427824 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step bonding agent with light activation
Number of subjects: 120
Study 17427824 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite DSC bonding agent with light activation
Number of subjects: 120
Study 17427824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual‐cured resin composite (Luxacore Dualcure)
Number of subjects: 120
Study 17427824 — intervention group
Group type: COMPARATOR
Intervention: Self‐cured resin composite (Luxacore)
Number of subjects: 120
Study 15752393 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + remifentanil (1 microg kg(‐1))
Number of subjects: 60
Study 15752393 — intervention group
Group type: COMPARATOR
Intervention: Propofol + fentanyl (2 microg kg(‐1))
Number of subjects: 60
Study 12442921 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and methotrexate
Number of subjects: 153
Study 12442921 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 153
Study 10225151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mm diameter Teflon platinum piston
Number of subjects: 200
Study 10225151 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mm diameter Teflon piston
Number of subjects: 200
Study 7675979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb)
Number of subjects: 0
Study 7675979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgold (a type of Ginkgo biloba extract)
Number of subjects: 0
Study 7675979 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 0
Study 2137644 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroprotective agents
Number of subjects: 0
Study 2137644 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of OA of the knee
Number of subjects: 0
Study 382152 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg t.d.s.
Number of subjects: 40
Study 382152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30116112 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional compression garment (18-21 mmHg) applied to one calf for 60 hours after exercise
Number of subjects: 15
Study 30116112 — intervention group
Group type: COMPARATOR
Intervention: Non-compressed calf
Number of subjects: 15
Study 26669417 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (20 minutes)
Number of subjects: 64
Study 26669417 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest for 20 minutes)
Number of subjects: 64
Study 24906585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (40 min, twice per week for 4 weeks)
Number of subjects: 25
Study 24906585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (one-time treatment)
Number of subjects: 25
Study 22295870 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal™ laryngeal mask airway (PLMA)
Number of subjects: 60
Study 22295870 — intervention group
Group type: COMPARATOR
Intervention: Classic™ laryngeal mask airway (cLMA)
Number of subjects: 60
Study 20307214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ophthalmic suspension 0.1%
Number of subjects: 56
Study 20307214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18547415 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulphadoxine‐Pyrimethamine (AQ+SP)
Number of subjects: 601
Study 18547415 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate + Amodiaquine (AS+AQ)
Number of subjects: 601
Study 18547415 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether‐Lumefantrine (AL)
Number of subjects: 601
Study 16038456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized bone graft-RBX (group A)
Number of subjects: 27
Study 16038456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized bone graft (group B)
Number of subjects: 27
Study 16038456 — intervention group
Group type: COMPARATOR
Intervention: RBX (group C)
Number of subjects: 27
Study 16038456 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 27
Study 12373468 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 106
Study 12373468 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 106
Study 10365743 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0
Study 10365743 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 10365743 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 10365743 — intervention group
Group type: COMPARATOR
Intervention: Picotamide, Indobufen, Low molecular weight heparins, Sulodexide, Defibrotide
Number of subjects: 0
Study 7771913 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride, 1.0 mg/kg per day
Number of subjects: 23
Study 2125153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3)
Number of subjects: 325
Study 2125153 — intervention group
Group type: EXPERIMENTAL
Intervention: The same regimen as R3 followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5)
Number of subjects: 325
Study 2125153 — intervention group
Group type: COMPARATOR
Intervention: The same as R5 but without rifampicin (Z5)
Number of subjects: 325
Study 7446621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation Method (OM)
Number of subjects: 566
Study 7446621 — intervention group
Group type: COMPARATOR
Intervention: Symptothermal Method (STM)
Number of subjects: 566
Study 31516033 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (800/150/200/10 mg)
Number of subjects: 1754
Study 31516033 — intervention group
Group type: COMPARATOR
Intervention: Boosted darunavir plus emtricitabine/tenofovir-disoproxil-fumarate
Number of subjects: 1754
Study 31647468 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive antismoking ads
Number of subjects: 1970
Study 31647468 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic antismoking ads
Number of subjects: 1970
Study 31647468 — intervention group
Group type: EXPERIMENTAL
Intervention: Price promotions
Number of subjects: 1970
Study 28645997 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-containing elastomeric infusion devices
Number of subjects: 115
Study 26165375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet
Number of subjects: 19
Study 26165375 — intervention group
Group type: COMPARATOR
Intervention: High glycemic load (GL) diet
Number of subjects: 19
Study 23225237 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg daily plus advice for exercise and lifestyle modification
Number of subjects: 99
Study 23225237 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 99
Study 23225237 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (normoglycemic)
Number of subjects: 99
Study 21511783 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site outreach education in intervention clinics
Number of subjects: 150
Study 21511783 — intervention group
Group type: COMPARATOR
Intervention: No outreach education in control clinics
Number of subjects: 150
Study 19497653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec (chlorhexidine-thymol varnish)
Number of subjects: 68
Study 19497653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16510610 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline HbA1c levels
Number of subjects: 27110
Study 16510610 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 27110
Study 15514506 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of running at 50% VO2max
Number of subjects: 0
Study 15514506 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of low-frequency EMS on the lower limb extensor muscles
Number of subjects: 0
Study 15514506 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 0
Study 11101186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder fluticasone propionate 200 microg once daily (QD)
Number of subjects: 242
Study 11101186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder fluticasone propionate 100 microg twice daily (BID)
Number of subjects: 242
Study 11101186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 9298513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg daily, PO)
Number of subjects: 4
Study 9298513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 7914737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microgram/kg i.v. (n = 15)
Number of subjects: 30
Study 7914737 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo i.v. (n = 15)
Number of subjects: 30
Study 3051880 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (100 mg daily)
Number of subjects: 10
Study 3051880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily)
Number of subjects: 10
Study 3051880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31264412 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 0
Study 29378106 — intervention group
Group type: EXPERIMENTAL
Intervention: Group preventive consultation in the School of a balanced nutrition
Number of subjects: 242
Study 23246022 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Number of subjects: 1491
Study 23246022 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 1491
Study 20622656 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS (oral nutritional supplement)
Number of subjects: 40
Study 18783301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ABT-335 135 mg/day and rosuvastatin (10 mg/day and 20 mg/day)
Number of subjects: 2400
Study 18783301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ABT-335 135 mg/day and atorvastatin (20 mg/day and 40 mg/day)
Number of subjects: 2400
Study 18783301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ABT-335 135 mg/day and simvastatin (20 mg/day and 40 mg/day)
Number of subjects: 2400
Study 18783301 — intervention group
Group type: COMPARATOR
Intervention: ABT-335 monotherapy
Number of subjects: 2400
Study 18783301 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy (rosuvastatin, atorvastatin, simvastatin)
Number of subjects: 2400
Study 16635593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (plant‐based, low‐fat diet; exercise; stress management) for 1 year
Number of subjects: 440
Study 16635593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for patients with DM
Number of subjects: 440
Study 16635593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for patients without DM
Number of subjects: 440
Study 14616319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.5, 1.0 and 1.5 MAC in 30% oxygen
Number of subjects: 26
Study 14616319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 MAC over a 90‐min period
Number of subjects: 26
Study 10948782 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacemaker in activated mode (DDD with optimized short AV delay)
Number of subjects: 83
Study 10948782 — intervention group
Group type: COMPARATOR
Intervention: AAI pacemaker in inactivated mode
Number of subjects: 83
Study 8919902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% at a dose of 0.5-1.0 mg/kg for spinal anesthesia
Number of subjects: 5
Study 8919902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5%
Number of subjects: 5
Study 8919902 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 5
Study 8919902 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with hyperbaric bupivacaine 0.5%
Number of subjects: 5
Study 1748115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis
Number of subjects: 54
Study 1748115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no antibiotic prophylaxis)
Number of subjects: 54
Study 6460587 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (ZIM)
Number of subjects: 8
Study 6460587 — intervention group
Group type: EXPERIMENTAL
Intervention: Norzimelidine (NZIM)
Number of subjects: 8
Study 6460587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6460587 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (ZIM) and Norzimelidine (NZIM)
Number of subjects: 8
Study 31266367 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths intervention
Number of subjects: 22
Study 31266367 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 22
Study 27824428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0
Study 27824428 — intervention group
Group type: COMPARATOR
Intervention: Internal standard (Ofloxacin)
Number of subjects: 0
Study 25403163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous cardiosphere‐derived cells (CDCs)
Number of subjects: 14
Study 25403163 — intervention group
Group type: COMPARATOR
Intervention: Standard palliation alone
Number of subjects: 14
Study 23076005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 20
Study 23076005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% and epinephrine 1:1,000,000
Number of subjects: 20
Study 23076005 — intervention group
Group type: EXPERIMENTAL
Intervention: Local tumescent anaesthesia 0.15% TLA: ropivacaine, lidocaine, saline solution plus epinephrine 1:1,000,000
Number of subjects: 20
Study 23076005 — intervention group
Group type: COMPARATOR
Intervention: 2% Lidocaine with 20 minutes tourniquet (Control Group)
Number of subjects: 20
Study 21781649 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 μg, p.o.)
Number of subjects: 12
Study 21781649 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast N-oxide
Number of subjects: 12
Study 21781649 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 12
Study 19303273 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg, three times daily for four weeks)
Number of subjects: 105
Study 19303273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin placebo, three times daily for four weeks)
Number of subjects: 105
Study 17803436 — intervention group
Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%/timolol 0.5%
Number of subjects: 30
Study 17803436 — intervention group
Group type: COMPARATOR
Intervention: dorzolamide 2%/timolol 0.5%
Number of subjects: 30
Study 15025736 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ‐68023 (high dose)
Number of subjects: 18
Study 15025736 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ‐68023 (low dose)
Number of subjects: 18
Study 15025736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11811431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spectacles
Number of subjects: 255
Study 11811431 — intervention group
Group type: COMPARATOR
Intervention: Hudson face mask
Number of subjects: 255
Study 11811431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spectacles (excluding male patients with abdominal surgery and muscle relaxants)
Number of subjects: 255
Study 9745191 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide in spray 1.25 mg
Number of subjects: 36
Study 9745191 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulphate 4 g infused in one hour, then 1 g each hour for a maximum of five hours
Number of subjects: 36
Study 8521205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chlorpromazine (CPZ) 0.1 mg/kg/dose, up to three doses
Number of subjects: 91
Study 8521205 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide (MC) 0.1 mg/kg/dose, up to three doses
Number of subjects: 91
Study 8521205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chlorpromazine (CPZ)
Number of subjects: 91
Study 8521205 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide (MC)
Number of subjects: 91
Study 2920498 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 6
Study 2920498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipemidic acid
Number of subjects: 6
Study 2920498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1054407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic dentifrice
Number of subjects: 120
Study 1054407 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentifrice
Number of subjects: 120
Study 30726862 — intervention group
Group type: COMPARATOR
Intervention: Glucose 2.5 g/day (g-group) for college students
Number of subjects: 41
Study 30726862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose 5 g/day (s-group) for college students
Number of subjects: 41
Study 30726862 — intervention group
Group type: COMPARATOR
Intervention: Fructose 2.5 g/day (f-group) for adults
Number of subjects: 41
Study 30726862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose 5 g/day (s-group) for adults
Number of subjects: 41
Study 28244002 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-space.net social networking intervention
Number of subjects: 347
Study 28244002 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 347
Study 26188394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (Jevtana)
Number of subjects: 29
Study 26188394 — intervention group
Group type: COMPARATOR
Intervention: AR-V7 positive CTCs
Number of subjects: 29
Study 22804103 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-to-family (FTF) program
Number of subjects: 0
Study 22804103 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater class attendance in FTF program
Number of subjects: 0
Study 21531741 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐pace mode
Number of subjects: 97
Study 19909427 — intervention group
Group type: EXPERIMENTAL
Intervention: hIVIgG
Number of subjects: 12
Study 19909427 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 12
Study 17024939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 with NaOCl pretreatment
Number of subjects: 14
Study 17024939 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond 2.1 without NaOCl pretreatment
Number of subjects: 14
Study 17024939 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond with NaOCl pretreatment
Number of subjects: 14
Study 17024939 — intervention group
Group type: COMPARATOR
Intervention: Single Bond without NaOCl pretreatment
Number of subjects: 14
Study 17024939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Prime & Bond 2.1 and Single Bond)
Number of subjects: 14
Study 14551014 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg per day E2 vaginal ring
Number of subjects: 333
Study 14551014 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg per day E2 vaginal ring
Number of subjects: 333
Study 14551014 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 333
Study 10701730 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF and sucralfate (n = 20)
Number of subjects: 40
Study 10701730 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate alone (n = 20)
Number of subjects: 40
Study 9347592 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic
Number of subjects: 7
Study 9347592 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 7
Study 8409337 — intervention group
Group type: EXPERIMENTAL
Intervention: Roferon A 3 MU administered subcutaneously 3 times weekly after hemodialysis for 6 months
Number of subjects: 13